MetLife, Inc. (MET) Earnings Call Transcript & Summary
November 6, 2025
What were the key takeaways from MetLife, Inc.'s November 6, 2025 earnings call?
In the third quarter of 2025, MetLife, Inc. reported adjusted earnings of $1.6 billion, or $2.37 per share, reflecting a 22% increase year-over-year. Revenue growth was driven by strong variable investment income and improved underwriting results in the Group Benefits segment. Management maintained a positive outlook, indicating that the fourth quarter is expected to be a record period for pension risk transfer transactions, with $12 billion already secured. Adjusted earnings guidance for the full fiscal year remains strong, supported by disciplined capital management and strategic initiatives under the New Frontier strategy.
What topics did MetLife, Inc. cover?
- Strong Variable Investment Income: MetLife reported variable investment income of $483 million, exceeding the quarterly outlook of $425 million, driven by private equity returns of 3%. CEO Michel Khalaf stated, "The greatest driver of our outperformance in the quarter was strong investment margins led by variable investment income."
- Group Benefits Recovery: The Group Benefits segment saw adjusted earnings of $457 million, up 6% year-over-year, attributed to improved underwriting results and seasonal dental profitability. Management noted a "230 basis point sequential improvement in our nonmedical health loss ratio," indicating a recovery in disability claims.
- Record Pension Risk Transfer Activity: MetLife has already secured $12 billion in pension risk transfer transactions for the fourth quarter, positioning it for a record performance. CFO John McCallion highlighted that this demonstrates "the trust the marketplace has in MetLife," reflecting strong demand for their retirement solutions.
- Asia Market Growth: Adjusted earnings from Asia were $473 million, a 36% increase year-over-year, with sales up 34% on a constant currency basis. Management emphasized that "sales surged driven by an outstanding 31% increase in Japan," showcasing strong product performance and distribution strength.
- Tax Law Impact in Mexico: Management discussed a notable charge related to a tax law change in Mexico, which will reduce adjusted earnings by approximately $50 million to $60 million in 2026. However, they expressed confidence that "this impact to the VAT change is isolated in nature, and it's temporary," expecting recovery by 2027.
What were MetLife, Inc.'s November 6, 2025 results?
- Adjusted Earnings: $1.6B (up 22% YoY, or $2.37 per share)
- Variable Investment Income: $483M (vs $425M guidance, driven by private equity returns)
- Group Benefits Adjusted Earnings: $457M (up 6% YoY)
- Asia Adjusted Earnings: $473M (up 36% YoY)
- Pension Risk Transfer Transactions: $12B (secured for Q4, record level)
- Direct Expense Ratio: 11.6% (below target of 12.1%)
MetLife's strong quarterly performance underscores its ability to leverage diversified business segments for growth. The positive momentum in variable investment income and pension risk transfer transactions presents significant catalysts for future earnings. However, the tax law change in Mexico poses a risk that investors should monitor closely as it may impact earnings in the coming year.
Earnings Call Speaker Segments
Thanks, operator, and good morning to all of you. We're glad you could join us today for MetLife's Third Quarter 2025 Earnings Call. Before we get started, I'd like to point you to the information on non-GAAP measures that's available on the Investor Relations section of metlife.com, in our earnings release, and in our quarterly financial supplements — please take a look at those. Joining us this morning are Michel Khalaf, President and Chief Executive Officer, and John McCallion, Chief Financial Officer and Head of MetLife Investment Management. Other members of senior management are also on hand to take part in today's discussion. Last night, we put out a set of quarterly supplemental slides, and you can find them on our website. John McCallion will walk through those slides during his prepared remarks. An appendix to the slides includes additional disclosures, GAAP reconciliations and other information, and we'd ask you to review that as well. Following the prepared remarks, we'll move to a Q&A session, which will wrap up at the top of the hour. As a reminder, please keep to one question and one follow-up. With that, I'll hand things over to Michel.
Thanks, John, and good morning to everyone joining us. MetLife announced robust third-quarter results yesterday evening, demonstrating the profit potential of our diverse portfolio of leading businesses and highlighting how our New Frontier strategy is delivering tangible benefits. The projections we shared during the second quarter materialized in the third quarter just as we expected. In particular, our flagship Group Benefits segment saw underwriting performance recover, driven by typical disability claims experience and stronger dental profitability due to seasonal factors. Variable investment income made its largest recent contribution to adjusted earnings amid quicker capital markets activity, realizing gains in private equity. Our worldwide retirement liability origination operation is performing at a high level, with expansion in the U.S., the U.K., and Japan, where our capital-efficient setup is fueling exceptional sales increases. Meanwhile, in Latin America, Accelerator, our creative digital solution for embedded insurance, keeps drawing in and securing additional strategic partners. Now for our quarterly numbers. Adjusted earnings came in at $1.6 billion, or $2.37 per share, representing a 22% rise per share compared to the same period last year. Notable items amounted to $18 million, or $0.03 per share, and encompassed our yearly actuarial assumption review plus a tax adjustment in Mexico. If you leave out the notable items, adjusted earnings came to $1.6 billion, which works out to $2.34 per share — a 21% improvement compared with the prior year. Strong investment margins drove much of our success this quarter, especially those coming from variable investment income, and we also saw higher volumes across several of our business segments. Variable investment income totaled $483 million, above the $425 million quarterly guidance we had expected, because private equity returns came in higher and reached 3% for the quarter. With variable investment income recovering, MetLife posted an adjusted return on equity of 16.7% once notables are excluded, a figure that better reflects the company's earning capacity and lands close to the top of our 15% to 17% target. On top of that, our direct expense ratio came in at 11.6% for the third quarter. Relative to the New Frontier pledge, we're well ahead of where we planned to be on that measure, and AI plus other advanced technologies are serving as a multiplier that accelerates the gains we're making in productivity and efficiency. Now turning to MetLife's individual businesses. Group Benefits adjusted earnings, excluding notable items, came to $457 million, which is 6% higher than a year ago, helped by steady underwriting results. Disability results returned to normal levels, while dental profitability was up in the quarter, in line with the seasonal profit pattern it typically follows. Consequently, we experienced a 230 basis point quarter-over-quarter enhancement in our nonmedical health loss ratio, boosting our assurance in delivering a total 400 basis points of improvement spanning the third and fourth quarters; in Retirement and Income Solutions, adjusted earnings, excluding notable items, were $423 million, a 15% rise from the same quarter last year, due to increased variable investment income. Chariot Re was formally introduced in the third quarter with an initial reinsurance deal of approximately $10 billion. This strategic collaboration assists in broadening MetLife's retirement liability origination capabilities in a capital-efficient way while simultaneously creating institutional assets for MetLife Investment Management. Liability balances overall in RIS climbed 3%. That strong outcome came from growth in the general account balance, which included structured settlement production — our best quarter ever, actually — plus higher volume in U.K. longevity reinsurance. No new pension risk transfer deals were reported by us during the third quarter. Even so, the fourth quarter looks like it will set a record, since we have already written $12 billion of PRT transactions, which shows how much trust the marketplaces place in MetLife. Our long-term view of the PRT business remains favorable. Several weeks back, we put out the findings from our yearly poll of pension plan sponsors. According to the survey, 94% of those sponsors who plan to derisk their portfolios anticipate fully divesting within the next 5 years. That marks the greatest percentage since we began the survey 10 years ago. Turning to Asia. Adjusted earnings, excluding notable items, came to $473 million, which is a 36% rise on a reported basis versus the prior year quarter. Sales climbed 34% on a constant currency basis, fueled by an outstanding 31% gain in Japan. Our competitive Japanese product portfolio, covering both foreign currency and yen-denominated retirement products, has won excellent traction across our multipronged distribution in that country. Going even further, constant currency sales in other Asia markets leapt 39%, led by Korea, China and India. Turning to Latin America: adjusted earnings, once you strip out notable items, were $222 million, which is a 2% increase. The region's adjusted PFOs totaled $1.7 billion, a gain of 11% whether measured on a reported or constant currency basis — evidence that business momentum keeps building across the region, especially in Mexico, Chile and Brazil. We recently added e-commerce leader MercadoLibre as a partner for our Accelerator digital platform in Mexico and Brazil. Throughout Latin America, our partner count now exceeds 20, and since the Accelerator platform launched it has produced more than $340 million in annualized premiums — one more powerful illustration of New Frontier in action. To wrap up, EMEA turned in a solid quarter once more, posting adjusted earnings that exclude notable items of $89 million — a 19% increase as reported, driven primarily by higher volumes. Just as we do in every third quarter, we released the 2024 value of new business, or VNB, figures. It's hard to exaggerate the significance of VNB to MetLife as a mechanism for upholding capital and pricing discipline worldwide. Over the years, the main application of VNB has fueled our shift toward a business that relies less on capital, with steady gains shown annually. Once again, last year's numbers are striking. During 2024, we allocated $3.4 billion toward originating new business — that remains the foremost priority for the capital we hold. The funds committed last year generated an average internal rate of return of 19%, alongside a payback period of 5 years. Our achievements with VNB aren't something that happens on their own. Achieving attractive IRRs on new business, combined with short payback windows, plays a direct role in enabling us to deliver a strong ROE and generate meaningful free cash flow. Keeping that in mind, we continue to oversee capital carefully — protecting liquidity and the resilience of our balance sheet, while returning surplus capital to shareholders. Our history here speaks for itself; over the last 5 years, we've returned close to $24 billion to shareholders via buybacks and common dividends. And the third quarter followed the same pattern. Through common stock dividends and share repurchases, we returned roughly $875 million to shareholders. Common stock dividends accounted for about $375 million, while repurchases of our common stock came to around $500 million. Adding approximately $150 million of repurchases done in October, our total share buyback year-to-date now stands at roughly $2.6 billion. At the end of the quarter, our holding companies held approximately $4.9 billion in cash and liquid assets. That figure includes about $700 million earmarked for debt maturities coming up soon, and it exceeds the $3 billion to $4 billion target cash buffer we've set. There's no doubt that deploying and managing capital has been vital to our past success, and it will stay vital as we keep carrying out our New Frontier strategy. We're working hard to complete 2 strategic transactions: buying PineBridge and selling a legacy block of variable annuities to Talcott Resolution Life. In both cases, we're fully engaged and expect to close during the fourth quarter. As we carry out our New Frontier strategic priorities, we're broadening our leadership in the areas where we hold the right to win. Our investment portfolio, our time-tested approach to credit and our steadfast dedication to risk management form the foundation of our strategic priorities. For 157 years, MetLife has steered through intricate and shifting credit markets, generating consistent investment results even amid stretches of considerable volatility. Today, though the credit environment remains reasonably stable and credit fundamentals resilient, we acknowledge that spreads are historically tight and, in certain respects, priced for perfection. Across our portfolio, we hold an up and quality bias, backed by active surveillance and disciplined underwriting. Having a wide-ranging, top-tier portfolio plus hands-on risk oversight means we're ready for all kinds of economic scenarios, so we can deliver regardless of what conditions arise in the markets. In closing, what we saw in the third quarter shows how MetLife can create outstanding value both for shareholders and stakeholders, and it highlights how powerful the New Frontier is as an engine for growth. Just as we do each year, we recently completed the annual stress test of our strategy together with our Board of Directors, and we came away certain that our strategy is the correct one for this moment. Sticking to reliable execution, maintaining stable capital levels and keeping costs in check will continue to reinforce and set apart our standing as a market leader, while also powering our standout value offering—one rooted in robust expansion and appealing returns paired with reduced risk. At this point, I'll turn it over to John, who will take you through the quarter in more depth.
Appreciate that, Michel, and hello everyone. I'll walk you through our third-quarter results and direct your attention to the 3Q '25 supplemental slides, which cover the key points of our financial performance, among them the details of our annual global actuarial assumption review; beyond that, I'll bring you up to speed on our value of new business metrics as well as our position on liquidity and capital. If you turn to Page 3, there's a side-by-side look at net income and adjusted earnings for the third quarter. There's a fresh line on our statements now: net activity attributable to ceded reinsurance arrangements. It reflects how ceded reinsurance has been used more and more since Chariot Re came on the scene in the third quarter of 2025, and it captures the resulting effect on net income. Much of what offsets that figure lives in accumulated other comprehensive income, or AOCI, and it largely tracks shifts in unrealized gains or losses on the portfolio that was reinsured and handed over to the reinsurer. Given all that, we see the bulk of the accounting here as lopsided, or lacking economic substance. Beyond that, several key factors explain why adjusted earnings differed from net income during this period: derivative-related net losses tied to gains in equity markets, climbing long-term rates, and a firmer U.S. dollar. Net investment losses came in roughly in line with prior quarters. Overall, our assessment continues to be that the credit backdrop is fairly steady. Toward the bottom of the table, two noteworthy items appeared that mostly canceled each other out, yielding a net boost to adjusted earnings of $18 million, equivalent to $0.03 per share. First, there's the matter of how an industry-wide tax issue in Mexico got settled — specifically, one involving value-added tax deductions tied to certain expenses for health insurance claims. That settlement, along with the accompanying modification to tax law, resulted in a $71 million after-tax charge during the third quarter of '25 within Latin America. Looking ahead to the fourth quarter, we anticipate an additional after-tax charge ranging from $20 million to $25 million. Then for 2026, we project that Latin America adjusted earnings will decline by approximately $50 million to $60 million, reflecting our recalibration of underlying rate assumptions in Mexico, while 2027 and subsequent years should see little to no effect. The second matter involves our yearly actuarial assumption review, which gave adjusted earnings a boost of $89 million. Let's turn now to Page 4. We'll walk you through how those effects showed up in adjusted earnings and net income for each segment in greater depth. Taken as a whole, the annual review's impact was small. At Retirement Income Solutions, or RIS, higher mortality gave our payout annuity business a lift. In Asia, experience came in better than expected in Japan, reflecting lower morbidity in accident and health products along with favorable lapse experience in life insurance. Turning to MetLife Holdings, we recorded favorable mortality in life insurance as well as favorable lapse rates in variable annuities. Let's now move to adjusted earnings by segment, which you'll find on Page 5. Here we present the third quarter year-over-year comparison of adjusted earnings, excluding notable items, broken out by segment and Corporate and Other. Everything I say about this slide will be on an ex notables basis. On an adjusted basis, we earned $1.6 billion, which works out to a 15% gain compared with a year earlier. The main forces behind that were stronger variable investment income along with solid growth in volume. Those gains were partly counterbalanced by underwriting that came in less favorable and by recurring interest margins that were lower than what we saw a year ago. Adjusted earnings per share came to $2.34, which is 21% higher. Disciplined capital management helped support that growth. Now on to the segments. In Group Benefits, we saw consistent growth along with better margins. Adjusted earnings reached $457 million, an increase of 6%. Better cost margins and higher volume were the primary factors, although weaker life underwriting results partially countered those gains. When you set aside the assumption review, the group life mortality ratio for the quarter was 83.3%. That figure falls below the bottom end of the 84% to 89% range we're targeting for 2025, but it compares unfavorably with the 82.4% recorded on the same basis during the prior year. For nonmedical health, the interest adjusted benefit ratio reached 72.5%, slightly exceeding the midpoint of our annual target band of 69% to 74%, and essentially matching the 72.4% figure from the third quarter of '24. Sequentially, this marked a 230 basis point improvement over the second quarter, driven mainly by the dental seasonality we had anticipated and an expected bounce back in disability. We still look for our nonmedical health ratio to keep improving in 4Q, thanks to the usual seasonal dip in dental utilization. On the top line, Group Benefits adjusted PFOs rose 3%, held back by roughly 1 percentage point because of how participating life contracts affected premiums; on top of that, sales climbed 5% year-to-date, with growth seen across most products. RIS kept up its strong momentum, helped by higher investment income. Adjusted earnings hit $423 million, a 15% increase year-over-year. Higher Variable Investment Income, or VII, was the main factor. On the RIS side, investment spreads reached 131 basis points. That's a 29 basis point increase versus the previous quarter, driven by stronger variable investment income. If you strip out VII, RIS spreads landed at 102 basis points, which is 1 basis point higher quarter over quarter. In addition, when we shifted about $10 billion of RIS liabilities into Chariot Re during 3Q of '25, that weighed on adjusted earnings — consistent with the $15 million to $20 million per quarter guidance we'd provided previously. The business momentum at RIS continues to be solid. Adjusted PFOs, excluding PRTs, were up 14%, mostly fueled by growth in structured settlements as well as U.K. longevity reinsurance sales. At the same time, spread earning general account liabilities grew 4% compared with a year ago, while total liability exposures increased 3%. And as Michel noted, we've already locked in a record amount of new PRT mandates during Q4 so far. Now to Asia. The segment put up strong results on every key metric. Adjusted earnings were $473 million, rising 36% and 37% on a constant currency basis. Higher variable investment income and volume growth were the main drivers. On top of that, results got a positive lift from a $30 million after-tax benefit tied to a model refinement for accident and health products in Japan. On a constant currency basis, general account AUM at amortized costs rose 6% compared with a year earlier, while sales climbed 34%. In Japan, which is the biggest market for us in that region, sales increased 31% on a constant currency basis, helped by product launches and enhancements made earlier in the year. Sales in other Asia markets also made a meaningful contribution, rising 39% year-over-year on a constant currency basis, with Korea and China leading the way. Latin America delivered solid top line growth along with resilient earnings. Adjusted earnings reached $222 million, up 2% both as reported and in constant currency. That gain mostly came from higher volumes across the region. On top of that, a favorable Chilean encaje return of 6% contributed to LatAm's strong results, despite coming in below the 8% recorded in 3Q of '24. Latin America's top line continues to perform well. Adjusted PFOs rose 11% on a reported and constant currency basis, while sales increased 15% in constant currency, with robust growth throughout the region, especially in Mexico, Chile and Brazil. In EMEA, volume growth was broad-based, fueling a double-digit rise in adjusted earnings. Our adjusted earnings came in at $89 million, which represents a 19% increase, or 17% when you strip out currency effects.
For EMEA, adjusted PFOs rose 11%, and on a constant currency basis they climbed 9%, while sales increased 24% on a constant currency basis, driven by strength in most markets, with Turkey, the Gulf and the U.K. leading the way. MetLife Holdings posted adjusted earnings of $190 million, a 12% gain, mainly because of higher variable investment income. Corporate and Other recorded an adjusted loss of $288 million in 3Q of '25, versus a loss of $249 million during the same period a year earlier. That rise came mostly from market-related employee costs, along with larger interest payments on outstanding debt. Regarding adjusted earnings, our effective tax rate came in at about 24% for the quarter, which falls at the low end of the 24% to 26% range we guided for 2025. If you turn to Page 6, the chart there presents pretax variable investment income over the last 5 quarters, and for the third quarter of 2025 it reached $483 million, topping the $425 million quarterly figure we had implied. Results were lifted by a 3% return from private equity, whereas real estate and other funds averaged roughly 50 basis points. Just to reiterate, private equity along with real estate and other funds are reported with a 1-quarter lag and are accounted for on a mark-to-market basis. On page seven, you'll see post-tax variable investment income broken out by segment, plus Corporate and Other, for the past five quarters. Every business segment keeps its own separate investment portfolio, built to closely align with the liability profile it supports. Most of the VII assets sit in Asia, RIS, and MetLife Holdings, which mirrors how long-term those obligations are. Total VII assets came to roughly $19 billion as of September 30, 2025. Asia made up more than 40% of that total, with RIS at about 30% and MetLife Holdings at roughly 20%. That mix shows how we think about asset allocation strategically, making sure each portfolio lines up with the duration and risk traits of the liabilities in its segment. Now let's move to expenses. On page 8, you can see how our direct expense ratio has moved over time. In the third quarter of 2025, that ratio came in at 11.6%. That's better than the 11.7% we posted in Q3 of '24, and it's well under the 12.1% we set as our target for the full year. We keep making the point that because quarterly results naturally bounce around, the full year direct expense ratio is the best gauge of how we're managing expenses. Still, what we delivered this quarter shows once again that we stay committed to keeping expenses disciplined and running efficiently, even as we grow responsibly across our businesses. Now let's look at Page 9. This chart shows MetLife's value of new business, or VNB, figures for our major segments, which we report once a year and highlight for the past 5 years. In 2024, we put $3.4 billion of capital toward backing new business initiatives, and that produced an average unlevered internal rate of return of roughly 19%, along with a payback period of 5 years; through this disciplined deployment of capital, we created approximately $2.6 billion in new business value. The 2024 VNB numbers show how we remain committed to directing funds into possibilities that deliver responsible growth and attractive returns; we view annual VNB as an essential gauge of our ability to lift ROE and accelerate free cash flow generation over time. Let me now take you through our cash and capital position, which is detailed on Page 10. MetLife continues to be well capitalized, holding strong liquidity that sits comfortably beyond the internal goals we set. At September 30, cash and liquid assets held at the holding companies came to $4.9 billion, which is above our target cash buffer ranging from $3 billion to $4 billion; giving back extra capital to our shareholders stays a priority, with total cash returns during the third quarter hitting about $875 million, made up of roughly $500 million from share repurchases and approximately $375 million from common stock dividends. Beyond those returns, holding company cash also captures the net effect of subsidiary dividends, debt issuances, operating expenses and other cash flows. When it comes to our U.S. On the entities side, preliminary statutory operating earnings for the first nine months of 2025 came in at about $2.1 billion, with net income of $1.3 billion. As of September 30, our estimated U.S. statutory adjusted capital on an NAIC basis stood at roughly $17.1 billion, essentially unchanged from the previous quarter. We anticipate the Japan solvency margin ratio will be near 740% as of September 30, although the final statutory filings aren't due for a few more weeks. Now, looking forward, we're pleased with the progress we've made in transitioning Japan toward ESR, a capital framework that closely mirrors the economic capital model we use to operate our business. From our initial work, we anticipate reporting an economic solvency ratio somewhere between 170% and 190% beginning March 2026; that ratio speaks to the strong capitalization of MetLife Japan, shown by its stand-alone AA- rating from S&P, along with how efficiently we manage capital. Over the past 5 years, we have pulled cash dividends out of Japan amounting to more than $4 billion. Before I finish, I want to mention that beginning in the fourth quarter, we intend to report MetLife Investment Management, or MIM, as a business segment of its own. Also, we intend to do away with MetLife Holdings as a stand-alone segment by folding it into Corporate and Other. Our New Frontier strategy aligns well with this new reporting framework. When we carry out this resegmentation, recasted historical financial results will be provided in early January, and that should leave you plenty of time to update your models ahead of the fourth quarter earnings call. In short, MetLife delivered a solid quarter, backed by durable momentum and healthy fundamentals across our diverse set of market-leading businesses. We achieved strong top line growth, maintained underwriting discipline and exercised prudent expense management, while also benefiting from stronger private equity returns. Furthermore, our value of new business metrics highlight the strategic, disciplined approach we take to allocating capital. With a solid balance sheet behind us and dependable production of free cash flow, we're set up nicely to pursue sensible expansion and generate appealing returns while taking on less risk, which builds lasting worth for our customers as well as our shareholders. So with that, I'll hand the call over to the operator so you can ask your questions.
My initial inquiry concerned sales in Asia. Could you give us more detail regarding the strength you observed? Which factors were the main drivers? Also, how far do you believe this momentum can keep going in the future?
Ryan, this is Lyndon speaking. Well, we're quite happy with the robust quarter we delivered across Asia; the entire Asia market rose by 34%. Allow me to add further detail. Beginning with Japan: year-over-year sales climbed 31%, and we introduced a few new offerings. In April we brought out a new single premium FX Life product, which keeps performing extremely well; beyond that, in August we rolled out a new yen variable life product, and the market has responded very favorably to it too. We've made product improvements as well. Earlier in the year we upgraded our single premium FX Annuity product, and measured against the previous year, it keeps performing strongly. So when you combine every product launch we've implemented plus the product improvements with the strength of our distribution, that is genuinely what fuels the robust growth we're seeing across both of our channels — bancassurance and the face-to-face channel — in Japan. Turning now to the remainder of Asia, sales increased 39% year-over-year there; and we're truly witnessing solid performance in Korea and China. In China, sales came in higher within the bancassurance channel, which has largely been powered by the fact that we've brought on some new key bank partners and also succeeded in penetrating existing bank partners; in Korea, we keep delivering reliably solid results. There, we're demonstrating strength in our U.S. dollar product sales, in our one variable life product, and in the face-to-face channels. So overall, good results; as we look forward, we anticipate this momentum carrying into the fourth quarter, and we anticipate surpassing the full year sales guidance for '25. I hope that's useful.
Great. Then, a fast question about how expenses vary by season. I believe the fourth quarter usually brings some of that pattern. Could you share roughly how big it might be?
Yes, Ryan, this is Michel. We're genuinely happy that our direct expense ratio landed significantly under the 12.1% goal we'd established in the outlook. Seasonality does play a role, with the fourth quarter running a bit above the first three. Our current outlook is that we'll land under that 12.1% figure — in fact, I'd say considerably under the 1.1 by the time the year closes. Two things are driving that, I'd note. First, back near the start of this year, because the environment looked so uncertain, we asked our teams to pull in the belt a bit and find ways to keep a tighter grip on spending, all without cutting back on anything we're putting into growth and strategic initiatives. The response has been fantastic, and we're really happy with it. We've also told the team to be sure some portion of those savings rolls over into next year and beyond. The second thing at play here has to do with technology. Across the past five years, more than $3 billion has gone into making our technology ecosystem simpler and more up to date, and that work has given us the base we needed to bring emerging technologies — AI among them — into our core processes, products and services. On top of that, we built an AI platform of our own that goes by the name MetIQ. Generative, agentic and classical AI capabilities all come together in that platform, which enables responsible solutioning throughout our business domains. App development and customer service are two examples to keep in mind. We've likewise given our employees and our associates tools, plus more training. The result of all this is productivity gains and additional efficiencies, and it's also part of why the direct expense ratio you see here is lower.
Starting off, regarding the $12 billion in PRT contracts you've secured during Q4 — does that represent a handful of big transactions or a bunch of smaller ones? Also, could you share your thoughts on the competitive dynamics in that space that have enabled you to capture so many deals?
Thanks, Tom. This is Ramy speaking. Our 2025 results in PRT have us quite happy. We've written over $14 billion up to now; and per what Michel said, $12 billion of that is landing in Q4, setting a record for us; these are a handful of sizable transactions. As you're aware, our focus is on the jumbo segment rather than the smaller segment. So picture those as jumbo-sized, not minor transactions. And the other — perhaps 3 additional points to consider that frame this record-setting quarter for us. First, we hold clear competitive edges within that jumbo segment. That means our balance sheet scale and our investment expertise. And Tom, when it comes to the jumbo segment, financial strength, disciplined risk management and a proven track record all matter greatly to plan sponsors and their advisers, and we're delighted to be earning the marketplace's confidence in this area and delivering a record quarter. The 2 remaining points I'd add here are, first, to restate our disciplined method for handling these transactions. We apply an M&A perspective to how we allocate capital here and assess the risk and return on every deal. So an emphasis on value is definitely present, and you'll notice we also report our VNB metrics, which capture that as well. And within PRT, we keep delivering ROEs in this line of business that support our enterprise ROE objectives. And perhaps the final point too, simply to frame this properly, this is likewise a quarter in which this victory nicely demonstrates how we're putting to work our retirement platform and our capital strategies that we described at our Investor Day; so we're delivering the power of our liability origination, our RIS platform. We're drawing on our own balance sheet, while simultaneously bringing in third-party capital to boost financial flexibility. So consider those transactions generating spread earnings for RIS plus extra growth and fee revenue for MetLife Investment Management. So it genuinely checks many of the boxes we outlined back at Investor Day concerning our approach here.
That’s useful context, and I appreciate it, Ramy. My follow-up is probably also for you. Could you talk about what’s driving the improvement beneath nonmedical health? I think a number of peers have experienced some volatility in group disability this quarter. Could you discuss how dental and disability break down, what you saw in Q3, and then why you remain confident that you can keep improving into Q4?
Thanks, Tom. We’re very happy as well with our underwriting results in group. And you saw us report a nonmedical health ratio down 230 basis points sequentially, which is a bit better than what we pointed to last quarter; so let me break that out for you with respect to disability specifically, and then Dental. I’d point to 2 drivers of the sequential improvement. First is the favorable seasonal utilization pattern in dental. We mentioned that last quarter, and it has shown up here in the third quarter; we also have the benefits of our pricing actions still flowing through to our bottom line; and I’d remind you that this seasonality is present in the fourth quarter too, which is why we expect to see further improvement in this ratio in Q4. Disability is doing well for us. It’s very consistent with our expectations. Incidents and claim severity are in line. We are seeing very strong recoveries; and I’d say that comes from investments we’ve made in various capabilities in disability over a number of years. So this is also coming through in very strong recoveries. So overall, consistent with what we discussed last quarter; and so think about that 400 basis points improvement that we mentioned, this 230 gets us more than halfway there toward the overall 400. I hope that helps.
Regarding PRT, does any portion of the $14 billion you intend to write this year flow into Chariot Re? And what would the difference in earnings impact look like depending on whether it goes into Chariot Re versus remaining on your balance sheet?
Suneet, this is John. To begin — Chariot Re was launched on 7/1; we moved slightly under $10 billion of liabilities into Chariot Re, and the whole launch took under — a bit less than or just over 12 months. So — we feel quite good about how far we've come. I think this ties back to the strategy we described at Investor Day and that Michel expressed, concerning how we view pairing our own capital with capital from third parties. We're seeing additional expansion in the retirement business. So it's difficult to say precisely whether this is Chariot or is — Chariot is something that continues. We're continuously engaged with them. That's essentially how it works. And that's going to be a component of — the way we speed up growth across our retirement platforms. It's — yet it isn't always so perfectly matched and things don't always coincide. So I'd respond yes, but to your question, I think one could make the case that we'll examine our overall asset growth more holistically and then bring in third-party capital to supplement it. And then I think the remarks we provided a quarter back regarding, like, the effect, the short-term effect on earnings is somewhere between $15 billion to $20 billion on the $10 billion deal. That's roughly an approximation of an earnings effect in any given quarter; so just so you have, like, a sensitivity, though we'd anticipate that being short-term in nature as we then replace that with other growth.
All right, that helps. So, Michel, I believe during your prepared comments you brought up the subject of an efficient capital structure over in Japan. Could you expand on that a bit for us? Is this something only Met does? And on a related note, regarding ESR and that figure of $170 million to $190 million, I'm wondering whether you're applying any modifications to the FSA's rules?
Yeah, this is John once more. Since your question pulls together a few pieces, perhaps I should address it. When we bring up the efficient structure, clearly what we mean is that our footprint in Bermuda is quite substantial. We've therefore made use of Bermuda for particular products. Getting to a more economic regime has been helped by doing so. We've kept expanding our sizable operations in Bermuda — our affiliate as well as, clearly, the introduction of Chariot Re. So that framework is something we've been drawing on. Then your question concerned ESR. Was it simply about how that ties into ESR — was that what you asked? I want to confirm I understood it properly.
Yeah. No, we're talking about that 170 to 190 figure. A few companies have mentioned adjustments specific to their own situations that get applied when those ratios are reported. That's the thing I was asking about.
All right. Yes, there are no adjustments in this case. It's simply the prescribed approach. The prescribed rules are what we're adhering to here. So that gives you the $170 million to $190 million. And look, as we've been doing — we've operated within an economic framework; both have always been used by us to sort of consider our products and the way we manage that business. In my remarks I mentioned that we've consistently paid dividends, including this year coming out of Japan; we've had $4 billion of distributions up to the holdco over the last 5 years. So this is simply the general range that we would anticipate running this company within.
Starting with Group Benefits. Could you describe what the competitive landscape and pricing look like right now, and where you expect that to take growth? At this stage, do you believe you're in a position to return to a longer-term growth outlook for 2026?
Thank you, Alex. What I'd say is the market remains competitive, yet pricing within it stays rational, and that combination means we consistently identify chances to expand, growing that business while keeping underwriting discipline and hitting our target returns. You've heard us mention this before, though I'd point out 2 particular characteristics that keep this environment both competitive and rational. Number one, these products are short-term, so underwriting outcomes show up relatively fast. That serves as a built-in restraint, so to speak, on how competition plays out. Number two, customers in this space want genuine answers that support their broader talent strategies and produce business results. So sure, price is important, yet they also want offerings that deliver strong experiences for their employees and boost productivity. Often, they're seeking to shift the administrative load tied to leave and absence. They'd like to do so with a carrier that's closely connected to them and simple to work with. They want to accomplish more using less. That means they're after bundled offerings spanning the full product lineup. And, well, we hold a leading position in this industry. As a result, we deliver everything just described and then some, which lets us generate solid growth, achieved through strong retention, favorable renewal pricing, and we can manage all of it while staying disciplined. So I'd say each of these elements is a genuinely positive trait that we — that the market possesses; plus we posted a 4% growth rate this quarter after you essentially strip out the effect of the <<inaudible>> contracts, and 4% on top of $25 billion in absolute terms is quite a meaningful figure, so we're very happy with the momentum this business has.
For the second question, could you share your perspective on what's been said lately regarding private credit investments in insurance? I believe a portion of that commentary centered on private letter ratings and the notion that ratings inflation might exist. So any statistics you could provide regarding your private credit portfolio and your approach to assigning ratings, that would also be useful.
Alex, this is John. I'll begin, and perhaps I'll turn to my colleague here to add further detail. Let me offer some general observations. As Michel mentioned earlier, first of all, we hold a positive view of the credit landscape at present. Fundamentals remain robust, and corporate earnings are solid. However, per what Michel said, spreads have grown narrow. That means you must remain highly attentive and rigorous when it comes to value and risk today. For our part, that typically translates into moving toward higher quality. Even within strategies that target higher yields, we're shifting toward quality. I came across that same article you mentioned. Honestly, the remarks in it were quite vague. It's difficult to analyze something like that, and I wouldn't attempt to do so in this setting. Still, speaking just for us, we rank among the top-tier managers of private assets and private credit. We've been engaged in this work for decades. Crucially, we've navigated credit cycles along the way, correct? Not everybody can claim that. These assets provide us with numerous advantages, and I'll bring in Chuck. Chuck serves as our Chief Investment Officer, and he can offer additional detail on certain specifics and our approach to underwriting.
To build on what John said first, his point is exactly right — we have invested heavily in this sector going way back. And when you hear everything being said out there, it matters to grasp that MIM handles its own underwriting. The main way we underwrite credit is through the work we do ourselves. Rating agencies aren't it, a rating letter isn't it. It's the underwriting we specifically perform. Investment grade describes the bulk of our corporate bonds, 95%; and for the exposure we carry to below investment grade, most of it has improved in quality. So taking all of that together — solid underwriting, solid experience, an emphasis on higher quality — the portfolio sits in a fairly strong spot.
The first thing I wanted to ask about was RIS, and really just your view on where the base spread goes from here. John, I believe you said it got better by a basis point. Still, looking ahead, what's your thinking on that base spread?
Like you mentioned, spreads came in at 131 basis points, with roughly 29 basis points of that attributable to VII. So we landed at 102%, which was in fact 1 basis point above Q2 and ahead of the guidance we'd provided; we had anticipated some seasonality in certain real estate that turned out less severe than we assumed, and a handful of other smaller favorable items also played a role in keeping us consistent. When we look at Q4, assuming nothing else changes, our expectation would be a spread level that holds steady versus Q3. One headwind we need to keep in mind, or at least be aware of, involves the sizable volume of PRT mandates we've brought in over this quarter, which can create a temporary quarterly drag while you reposition assets, and that might amount to a couple of basis points, if anything. Still, taking everything into account, relatively flat is, I'd say, where our view sits right now.
That helps. Now, for my second question — I believe Brighthouse put out a press release this morning indicating that Aquarian is expected to take the company over. As I understand it, MIM manages some of Brighthouse's assets. I just wanted to verify if there could be any additional effects on MetLife. My assumption is that it wouldn't involve AUM you oversee, but is there anything else worth considering going forward?
Yeah. We came across that report as well, and I'd say congrats to the team. Naturally, everything stayed in the realm of speculation until it wasn't — and if it does turn out to be true, well, a tremendous amount of effort went into making something like that happen. So we're definitely pleased, and we want to give the team credit for all the work they put in. From our standpoint, things with Brighthouse have been — we share a strong partnership with them. We clearly go way back together, so that connection holds a special spot for us. That said, we bring some truly distinctive asset management strengths to the table that we believe support their strategic goals. At this moment, the important connection tied to what you asked about is the one we have on the asset management side, and we're eager to make the most of that partnership, collaborating with them so we can assist in reaching their strategic goals.
Regarding MIM, could you talk about how the business performed during this year and what third-party flows have looked like?
Joel, it's been a good year. Honestly, if we broke down the year into its first and second halves, the first half was somewhat muted, simply because of volatility in the market. On top of that, the PineBridge announcement likely slowed things down somewhat early in the year, but the team has put in tremendous effort to educate the external environment. And then we saw — our second half was strong. On total assets under management, I think we're just over $630 billion of AUM, and above $200 billion when it comes to third-party assets. So — and flows during the second half have been very strong. So what lies ahead for MIM has us very excited. And obviously, it's one of our strategic initiatives to accelerate growth of — and the team has been working very hard and is excited to become our own segment come next year.
Understood. Then a few questions regarding LTC. To begin with, were there any significant modifications made to the assumptions? A few competitors have shown some unfavorable incidence patterns. I'm not certain how that is developing for your company. Also, is there anything new regarding the risk transfer sector for that line of business?
Yes, certainly. I'll begin, after which I'll pass it to Ramy so he can share his perspective on the marketplace. So generally speaking, the actuarial assumption review came in quite restrained, marginally favorable on the whole, a bit favorable in RIS where increased mortality provided a benefit and — subsequently in Asia, beneficial outcomes regarding morbidity and lapse rates. After that, in Holdings, we truly saw beneficial life results along with beneficial lapse results on VA, an extremely small LTC figure of 2 million after tax. Therefore, I believe the block keeps delivering strong results. The ADE matches what we would normally anticipate. Now I'll pass it to Ramy so he can provide some insight into what he is observing in the marketplace.
Appreciate that, John. Like we've mentioned previously, we do evaluate — and will keep evaluating — chances to move risk off our books; and obviously, we're paying close attention to the risk transfer deals that have happened lately, so we're involved and we keep examining that space. That said, we're going to stay extremely disciplined as we weigh these possibilities. Our book of business is managed very carefully. It's strongly capitalized and strongly reserved. Our rate action program keeps performing well, which lets us secure the premium growth this book requires; therefore, when we consider any possible deal, the price matters a great deal. And in the end, whatever deal we might do has to be accretive for us in terms of shareholder value.
Might you walk us through when the effects of Mexico's new tax legislation will start to show up?
Sure, Eric here. As John said, during this quarter we recorded a sizable charge tied to the amendment of Mexico's tax rules; let me begin, then, with some context on that item. Over the last several years, Mexico's tax administrators have disputed the VAT deductions claimed on particular expenses linked to insurance claims. And while those talks carried on across multiple years, essentially nothing moved forward until these last several weeks, when an agreement was struck between the government and the industry, with the modification taking effect from 2025 onward. That amendment to the tax code cleared the legislator only last week. For MetLife, this insurance-wide shift touches just our health offering. The altered VAT deductions produce meaningful effects during 2025, with a smaller effect during 2026. As we move into the new regime, earnings impact should then become minimal to nonexistent by 2027. We're already at work revising our underlying rate assumptions for this product that renews annually, together with further management steps that should soften the transition's effect; based on what we've seen, moreover, this market has proven quite resilient and rational, which leaves us confident we'll get through it fast. Our Mexican operation is robust. Ours is a big, highly diversified franchise, and we trust our capacity to keep producing that robust performance. To sum up, the VAT change's effect stands alone in character and won't last; by 2027, we anticipate returning to our run rate and the region's growth path. Hope that answers it.
All right, and beyond that, in Asia you recorded certain favorable revisions to assumptions. Could any portion of those persist going forward?
Wilma, this is John. No — as a rule, those are entirely one-time in character.
Good morning to all of you, and thanks for being here. We're eager to keep the conversation going as this quarter unfolds.
That brings us to the end of today's conference call. We appreciate everyone for joining in. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete MetLife, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to MetLife, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.